HIV Clinical Trial
Official title:
Effectiveness of Mobile Phone Technology in Improving Adherence and Treatment Outcomes Among HIV Positive Patients on Antiretroviral Therapy (ART) in Malaysia
The objective of this study was to determine the effectiveness of mobile phone technology (SMS and telephone call reminders) in improving adherence and treatment outcomes among HIV positive patients on ART in Malaysia.
This study was a 2 arm, parallel group, randomized single blind clinical trial involving 242
randomly selected and allocated adult Malaysian HIV positive patients who were enrolled into
Antiretroviral Therapy (ART) care at Infectious Disease Clinic of Hospital Sungai Buloh,
Malaysia. Recruitment commenced in January 2014 and follow up ended in December 2014. Each
individual patient was followed up for a period of 6 months on ART. A reminder module
(delivered via Short Message Service (SMS) and telephone call reminders) was developed based
on the Theory of Planned Behavior. The reminder module which included standardized weekly SMS
medication reminders (sent at 9am every Monday); SMS reminder 3 days prior to scheduled
clinic appointments (individualized and sent at lunch time), and an average of 90sec lunch
hour telephone call reminders a day prior to scheduled clinic appointment (in addition to
standard care - routine adherence counselling) was delivered consistently for 24 weeks to
respondents in the intervention group by two trained PLHIV (research assistants) while
respondents in the control group received standard care only. Each patient in the
intervention group had a minimum of three (during clinic visits at month 1, month 3 and month
6) individual counselling sessions with the research assistants lasting an average of 15
minutes per encounter. To ensure confidentiality, typical medication reminder text messages
included a short slogan in Malay language "Apa khabar" "Ini untuk menberithau anda ubat"
meaning "How are you?" "This is to remind you of your medications". Appointment reminder text
message was "Apa khabar" "Tolong ingat tarikh temu janji lusa" meaning "How are you?"
"Remember your appointment day after tomorrow" and telephone conversation was standardized
and short, with the message "Apa khabar" "Tolong ingat tarikh temu janji besok" meaning "How
are you?" "Remember your appointment tomorrow". Patients were not required to provide any
responses to the text messages. However, a log of text message communications and telephone
calls was recorded and kept.
Upon enrollment and randomization to a treatment arm, baseline data on socio-demographic
factors, clinical symptoms and adherence behavior of respondents was collected using
modified, pre-validated, reliable, self-administered Adult AIDS Clinical Trial Group (AACTG)
adherence questionnaire. The baseline medication adherence questionnaire consisting of nine
sections was used to collect data on patient's understanding and level of preparedness to
take HIV medications, level of psychosocial support from their friends and families, reasons
for missing medications as well as period and number of missed medications. Other information
collected were on patient's psychosocial symptoms and well-being, history of drug and alcohol
use, socio-demographic characteristics, source of HIV infection and disclosure status, and
review of their symptoms in the past 30 days. Responses to questions in sections A - E1 were
graded on a 4-point Likert scale, sections E2 and I on a 5-point Likert scale, section F on a
multiple scale (multiple choice, 2-point and 4-point scales), H on a 2-point scale, while
section G had 5 questions on socioeconomic and demographic characteristics.
Baseline weight, blood pressure, CD4 count, Viral load, as well as results of renal profile
and liver function tests were also collected and recorded.
Adherence measurement was repeated at 3 and 6 months follow-up using self-administered AACTG
follow-up adherence questionnaires which consisted of eight sections (sections A - H) and a
total of 49 questions graded on a combination of Likert and "Yes" or "No" scales, used for
assessing how well the patient has adhered to their medications and specific instructions
about their regimen within the past 3 months, with particular emphasis on the past four days.
It also contained a review of their symptoms during the past four weeks as well as their
current TB status and OI index. Section A consisted of a review of the respondent's current
medications, by evaluating their understanding and knowledge of the treatment regimen in
terms of drug name, frequency and strength of dosage, how long the patient has been on the
regimen, number of pills per dose as well as number of doses missed in the past four days.
This section was completed in a collaborative manner between the study personnel and the
patient. Responses to questions in sections B, C, D & H were graded on a 5-point Likert
scale, E on a 2-point scale, F on a 6-point scale, and G on a 4-point scale.
CD4 count, viral load, weight, full blood count, liver function, renal profile and blood
pressure measurements were repeated at 6 months follow-up period, and the results retrieved
from laboratory records.
Adherence scores were calculated using a standardized adherence index formula adopted from
Reynolds et al.(2007). Data on regularity of respondents' scheduled clinic visits was
obtained by the research assistants (for whom access was duly sought and provided by the
hospital management) from the hospital's electronic medical records system using standardized
data extraction forms and corroborated with drug refill appointments from pharmacy records.
The research assistants accessed and recorded onto the data extraction forms, information on
patient's TB status, opportunistic infection (OI) index and body weight from clinicians'
notes in the electronic medical record system. Data extraction forms were reviewed
periodically for completeness, correctness and accuracy by the site study coordinator.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
| Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
| Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
| Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
| Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
| Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
| Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
| Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
| Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
| Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
| Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
| Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
| Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
| Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
| Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
| Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
| Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
| Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
| Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |